{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T23:17:04Z","timestamp":1764717424832,"version":"3.46.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Drug\u2013drug interactions (DDIs) are a major cause of preventable adverse drug events. However, the clinical relevance of specific DDIs is often uncertain due to limited evidence beyond preclinical findings and pharmacokinetic studies. In this editorial, we discuss the recent study by Bea et\u00a0al. (Am J Epidemiol. 2025;000(00):0000-0000), which assessed whether the pharmacologic interaction between hydrocodone and non-dihydropyridine calcium-channel blockers is associated with the risk of opioid overdose, finding no increased risk. We highlight the methodological strengths of the study, including the use of a control precipitant, the consideration of the order of drug initiation in concomitant use, and the application of multiple exposure definitions. At the same time, we outline remaining challenges\u2014both in this study and more broadly in the DDI field\u2014such as the appropriate selection of control precipitants and selection bias due to depletion of susceptibles. Finally, we briefly discuss potential applications of novel pharmacoepidemiologic methods for DDI studies and also ways to strengthen the rationale for DDI studies and prioritize study questions. Given the rising rates of polypharmacy that lead to increased concomitant use of medications potentially interacting with each other, pharmacoepidemiology is well positioned to generate clinically actionable evidence to guide medication safety.<\/jats:p>","DOI":"10.1093\/aje\/kwaf222","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T12:07:46Z","timestamp":1760011666000},"page":"3620-3623","source":"Crossref","is-referenced-by-count":0,"title":["Invited commentary: building rigorous clinical evidence for drug\u2013drug interactions"],"prefix":"10.1093","volume":"194","author":[{"given":"Paraskevi","family":"Tassopoulou","sequence":"first","affiliation":[{"name":"Institute of Clinical Pharmacology and Toxicology, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin , Berlin ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6005-4006","authenticated-orcid":false,"given":"Antonios","family":"Douros","sequence":"additional","affiliation":[{"name":"Institute of Clinical Pharmacology and Toxicology, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin , Berlin ,","place":["Germany"]},{"name":"Department of Epidemiology, Biostatistics and Occupational Health, McGill University , Montreal, QC ,","place":["Canada"]},{"name":"School of Epidemiology and Public Health, University of Ottawa , Ottawa, ON ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,10,13]]},"reference":[{"issue":"4","key":"2025120218125971100_ref1","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1111\/bcp.15970","article-title":"Drug\u2013drug interactions and the risk of adverse drug reaction-related hospital admissions in the older population","volume":"90","author":"Hughes","year":"2024","journal-title":"Br J Clin Pharmacol."},{"issue":"1","key":"2025120218125971100_ref2","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12911-022-01783-z","article-title":"Overall performance of a drug\u2013drug interaction clinical decision support system: quantitative evaluation and end-user survey","volume":"22","author":"Van De Sijpe","year":"2022","journal-title":"BMC Med Inform Decis Mak."},{"issue":"6","key":"2025120218125971100_ref3","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1002\/pds.1351","article-title":"Hospitalisations and emergency department visits due to drug\u2013drug interactions: a literature review","volume":"16","author":"Becker","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"2025120218125971100_ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.923939","article-title":"Adverse drug reactions and correlations with drug\u2013drug interactions: a retrospective study of reports from 2011 to 2020","volume":"13","author":"Jiang","year":"2022","journal-title":"Front Pharmacol."},{"issue":"2","key":"2025120218125971100_ref5","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/s1086-5802(16)31229-3","article-title":"Drug-related morbidity and mortality: updating the cost-of-illness model","volume":"41","author":"Ernst","year":"2001","journal-title":"J Am Pharm Assoc."},{"issue":"2","key":"2025120218125971100_ref6","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.annepidem.2011.10.010","article-title":"Prescription medication use among normal weight, overweight, and obese adults, United States, 2005-2008","volume":"22","author":"Kit","year":"2012","journal-title":"Ann Epidemiol."},{"issue":"1","key":"2025120218125971100_ref7","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1517\/14740338.2013.827660","article-title":"Clinical consequences of polypharmacy in elderly","volume":"13","author":"Maher","year":"2014","journal-title":"Expert Opin Drug Saf."},{"issue":"9","key":"2025120218125971100_ref8","doi-asserted-by":"publisher","first-page":"e2432649","DOI":"10.1001\/jamanetworkopen.2024.32649","article-title":"Managing drug-drug interactions\u2014so many drugs, so little evidence","volume":"7","author":"Mehta","year":"2024","journal-title":"JAMA Netw Open."},{"issue":"3","key":"2025120218125971100_ref9","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1080\/17425255.2024.2322134","article-title":"Exploring the level of agreement among different drug\u2013drug interaction checkers: a comparative study on direct oral anticoagulants","volume":"20","author":"Carollo","year":"2024","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"2025120218125971100_ref10","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwaf198","article-title":"Risk of opioid overdose associated with concurrent use of hydrocodone and CYP3A4-inhibiting calcium channel blockers: a population-based cohort study","author":"Bea","year":"2025","journal-title":"Am J Epidemiol."},{"key":"2025120218125971100_ref11","doi-asserted-by":"crossref","DOI":"10.15620\/cdc\/170565","volume-title":"Drug Overdose Deaths in the United States, 2003\u20132023","author":"Garnett","year":"2024"},{"issue":"3","key":"2025120218125971100_ref12","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1046\/j.1365-2125.2003.02002.x","article-title":"CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes","volume":"57","author":"Hutchinson","year":"2004","journal-title":"Br J Clin Pharmacol."},{"issue":"1","key":"2025120218125971100_ref13","doi-asserted-by":"publisher","DOI":"10.1002\/pds.70088","article-title":"Evaluation of drug\u2013drug interactions in pharmacoepidemiologic research","volume":"34","author":"Chen","year":"2025","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"1","key":"2025120218125971100_ref14","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1002\/cpt.277","article-title":"Pharmacoepidemiologic methods for studying the health effects of drug\u2013drug interactions","volume":"99","author":"Hennessy","year":"2016","journal-title":"Clin Pharmacol Ther."},{"issue":"3","key":"2025120218125971100_ref15","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s40471-024-00347-1","article-title":"Methodological considerations on the use of cohort designs in drug-drug interaction studies in pharmacoepidemiology","volume":"11","author":"Dimakos","year":"2024","journal-title":"Curr Epidemiol Rep."},{"volume-title":"StatPearls","year":"2025","author":"Fahie","key":"2025120218125971100_ref16"},{"volume-title":"StatPearls","year":"2025","author":"Talreja","key":"2025120218125971100_ref17"},{"issue":"9","key":"2025120218125971100_ref18","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1111\/jch.14709","article-title":"Amlodipine in the current management of hypertension","volume":"25","author":"Wang","year":"2023","journal-title":"J Clin Hypertens."},{"issue":"10","key":"2025120218125971100_ref19","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1007\/s00228-025-03883-x","article-title":"Effectiveness and safety of concomitant use of direct oral anticoagulants and antiarrhythmic drugs: a systematic review of observational studies","volume":"81","author":"Meinert","year":"2025","journal-title":"Eur J Clin Pharmacol."},{"issue":"3","key":"2025120218125971100_ref20","doi-asserted-by":"publisher","first-page":"e243208","DOI":"10.1001\/jamanetworkopen.2024.3208","article-title":"Concomitant use of selective serotonin reuptake inhibitors with oral anticoagulants and risk of major bleeding","volume":"7","author":"Rahman","year":"2024","journal-title":"JAMA Netw Open."},{"issue":"4","key":"2025120218125971100_ref21","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s40471-015-0053-5","article-title":"The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application","volume":"2","author":"Lund","year":"2015","journal-title":"Curr Epidemiol Rep."},{"issue":"4","key":"2025120218125971100_ref22","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1002\/pds.4107","article-title":"Prevalent new-user cohort designs for comparative drug effect studies by time-conditional propensity scores","volume":"26","author":"Suissa","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"5","key":"2025120218125971100_ref23","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1097\/EDE.0000000000001628","article-title":"The prevalent new-user design for studies with no active comparator: the example of statins and cancer","volume":"34","author":"Suissa","year":"2023","journal-title":"Epidemiology."},{"issue":"10","key":"2025120218125971100_ref24","doi-asserted-by":"publisher","DOI":"10.1002\/pds.70014","article-title":"The prevalent new-user design to study drug-drug interactions: the example of sulfonylureas and warfarin interaction on the risk of severe hypoglycemia","volume":"33","author":"Wang","year":"2024","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"10","key":"2025120218125971100_ref25","doi-asserted-by":"publisher","DOI":"10.1002\/pds.70223","article-title":"Demystifying clone-censor-weighting to studying treatment initiation windows: an example using publicly available synthetic medicare claims data","volume":"34","author":"Webster-Clark","year":"2025","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"11","key":"2025120218125971100_ref26","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1111\/j.1553-2712.2000.tb00483.x","article-title":"Physician versus computer knowledge of potential drug interactions in the emergency department","volume":"7","author":"Langdorf","year":"2000","journal-title":"Acad Emerg Med."},{"issue":"5","key":"2025120218125971100_ref27","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s11095-020-02801-3","article-title":"Comparison of signal detection algorithms based on frequency statistical model for drug-drug interaction using spontaneous reporting systems","volume":"37","author":"Noguchi","year":"2020","journal-title":"Pharm Res."},{"issue":"5","key":"2025120218125971100_ref28","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1002\/cpt.1507","article-title":"Clopidogrel drug interactions and serious bleeding: generating real-world evidence via automated high-throughput pharmacoepidemiologic screening","volume":"106","author":"Leonard","year":"2019","journal-title":"Clin Pharmacol Ther."}],"container-title":["American Journal of Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/aje\/advance-article-pdf\/doi\/10.1093\/aje\/kwaf222\/64656126\/kwaf222.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/aje\/article-pdf\/194\/12\/3620\/64656126\/kwaf222.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/aje\/article-pdf\/194\/12\/3620\/64656126\/kwaf222.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T23:13:01Z","timestamp":1764717181000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/aje\/article\/194\/12\/3620\/8284763"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,13]]},"references-count":28,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,10,13]]},"published-print":{"date-parts":[[2025,12,2]]}},"URL":"https:\/\/doi.org\/10.1093\/aje\/kwaf222","relation":{},"ISSN":["0002-9262","1476-6256"],"issn-type":[{"type":"print","value":"0002-9262"},{"type":"electronic","value":"1476-6256"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,10,13]]}}}